Comparison 1. Fenofibrate vs placebo (5 year).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Progression of diabetic retinopathy	1	1012	Risk Ratio (IV, Fixed, 95% CI)	0.86 [0.60, 1.25]
1.1.1 With overt retinopathy at baseline	1	208	Risk Ratio (IV, Fixed, 95% CI)	0.21 [0.06, 0.71]
1.1.2 Without overt retinopathy at baseline	1	804	Risk Ratio (IV, Fixed, 95% CI)	1.00 [0.68, 1.47]
1.2 Incidence of overt retinopathy	2	1580	Risk Ratio (IV, Fixed, 95% CI)	0.91 [0.76, 1.09]
1.3 Incidence of DMO	1	850	Risk Ratio (IV, Fixed, 95% CI)	0.39 [0.12, 1.24]
1.4 Additional treatments for diabetic retinopathy (any laser)	1	9764	Risk Ratio (IV, Fixed, 95% CI)	0.70 [0.58, 0.85]
1.5 Additional treatments for diabetic retinopathy (focal/grid laser)	2	11358	Risk Ratio (IV, Fixed, 95% CI)	0.69 [0.56, 0.86]
1.6 Additional treatments for diabetic retinopathy (panretinal photocoaculation)	2	11347	Risk Ratio (IV, Fixed, 95% CI)	0.67 [0.51, 0.89]
1.7 Additional treatments for diabetic retinopathy (vitrectomy)	1	850	Risk Ratio (IV, Fixed, 95% CI)	1.96 [0.18, 21.56]
1.8 Discontinuation of the treatment	2	15226	Risk Ratio (IV, Fixed, 95% CI)	1.08 [1.01, 1.15]
1.9 Adverse effects (serious adverse event)	2	15226	Risk Ratio (IV, Fixed, 95% CI)	1.55 [1.05, 2.27]
1.10 Adverse effects (rhabdomyolysis)	1	9764	Risk Ratio (IV, Fixed, 95% CI)	3.00 [0.31, 28.87]
1.11 Adverse effects (hepatic disorder)	2	15226	Risk Ratio (IV, Fixed, 95% CI)	0.95 [0.69, 1.32]
1.12 Adverse effects (pancreatitis)	1	9764	Risk Ratio (IV, Fixed, 95% CI)	1.74 [1.04, 2.90]
1.13 Adverse effects (pulmonary embolism)	2	15226	Risk Ratio (IV, Fixed, 95% CI)	1.66 [1.07, 2.57]
1.14 Adverse effects (myositis)	1	9764	Risk Ratio (IV, Fixed, 95% CI)	2.00 [0.18, 22.08]
1.15 Adverse effects (renal disease needing dialysis)	1	9764	Risk Ratio (IV, Fixed, 95% CI)	0.76 [0.40, 1.46]
1.16 Adverse effects (deep‐vein thrombosis)	2	15226	Risk Ratio (IV, Fixed, 95% CI)	1.40 [0.97, 2.02]